This is a working overview of drug affinity complex, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Kipa-Williams enjoyed working with Samson, as they got along well and he believed that showed on-screen as Ari and Mia reconcile. He also praised Barrett and explained how they got the chance to explore their characters' histories together, saying "you'll get to see a softer side of Ari in the way that Sam plays her character. And I think people will be surprised at the father figure that he has forgotten he is, or was." The first test of Ari and Mia's new relationship is his involvement with a criminal gang headed up by Paul (Jack Finsterer), which leads to the kidnapping of Chloe, Nikau, Bella, and Ryder Jackson (Lukas Radovich). Mia decides to leave the Bay with Chloe and tells Ari that she regrets letting him back into her life. Kipa-Williams commented that "Ari is heartbroken – he's faced with losing the love of his life." He sympathised with Mia, who is angry about her daughter being kidnapped. He also pointed out that Mia thought Ari had changed, so it "pains" her to think that he is still the same man who could end up in prison again. As Ari is walking along the road, he calls Chloe before she leaves town, and is struck by a car driven by Paul who then speeds off. Kipa-Williams said Ari is "blindsided" by the attack and described it as "a ruthless hit-and-run". Ari suffers multiple injuries and has to be placed in a medically induced coma due to a bleed on the brain. Following Ari's recovery, writers scripted a pregnancy for Mia after the couple agree to try for a baby.
=== Unproven treatments === Botulinum toxin A injections, platelet-rich plasma injections and prolotherapy remain controversial. Dry needling is under consideration. A systematic review of available research found limited evidence of effectiveness. The studies were reported to be inadequate in quality and too diverse in methodology for a firm conclusion.However, later evidence suggested that dry needling may help reduce pain and improve function, particularly over longer follow-up periods. A combination of plantar fasciitis stretching and botulinum toxin showed an increase in improvement and functionability.
== History and taxonomy == Penicillium digitatum is a species within the Ascomycota division of Fungi. The genus name Penicillium comes from the latin word "penicillus", which means brush, referring to the branching appearance of the asexual reproductive structures found within this genus. As a species, P. digitatum was first noted as Aspergillus digitatus by Christiaan Hendrik Persoon in 1794, who later adopted the name Monilia digitata in Synopsis methodica fungorum (1801). The synonym M. digitata can also be found in the writings of Elias Magnus Fries in Systema Mycologicum. However, the current binomial name comes from the writings of Pier Andrea Saccardo, particularly Fungi italici autographie delineati et colorati (1881).
Sources: en.wikipedia.org
Also, this tail movement can increase the number interactions between the histone tail and the DNA, increasing likelihood of nucleosome formation and potentially leading to the creation of higher-order chromatin structure. In trans, P38 leads to the opposite effects: allowing for Set2 to methylate K36. Set2 is only affected by isomerization of P38 when creating a trimethylated K36 (commonly written as K36me3), however, and not K36me2. Fpr4 also binds to P32 in H4, though its effects are minimal. In mammalian cells, the isomerization of H3P30 interacts with the phosphorylation of H3S28 (serine in the 28 position of histone H3) and the methylation of H3K27. hFKBP25 is a PPIase that is a homolog for Fpr4 in mammalian cells and is found to commonly be associated with the presence of HDACs. Cyp33 is a cyclophilin that has the ability to isomerize H3 proline residues at P16 and P30 positions. Histones H2A and H2B also have multiple proline residues near amino acids that when modified affect the activity surrounding the histone.
== Function == Serpin A12 is a protease inhibitor with an approximate weight of 47 kDa and is a member of the adipokine family of cytokines excreted by adipose tissue. Members of this family regulate a number of cellular processes, such as inflammation mediation and insulin resistance. Made up of 414 amino acids, its main function is modulating the insulin inhibiting protease KLK7, mainly in adipose tissue. Among other functions, Serpin A12 performs insulin-sensitizing actions. Serpin A12 treatment of obese and insulin-resistant mice has been shown to decrease the expression of insulin resistance genes in white adipose tissue as well as improving carbohydrate resistance. Serpin A12 also increases bone density, which helps prevent osteoporosis. It does so by regulating osteoblasts, assisting in their mineralization of the bone matrix, thus balancing bone formation with bone resorption.
=== Names === Etilefrine is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while étiléfrine is its DCFTooltip Dénomination Commune Française and etilefrina is its DCITTooltip Denominazione Comune Italiana. In the case of the hydrochloride salt, its generic name is etilefrine hydrochloride and this is its BANMTooltip British Approved Name and JANTooltip Japanese Accepted Name. Synonyms of etilefrine include ethylnorphenylephrine, ethylphenephrine, etiladrianol, aethyladrianol, and M-I-36. Brand names of the drug include Effortil, Circupon, Apocretin, Palsamin, Kertasin, Pressoton, Effoless, and Sanlephrin.
At the Congress of Vienna of 1814–1815, Austria's representative, Prince von Metternich, detected a threat to this status quo in the Austrian Empire through nationalists' demands for independence from the empire. While Vienna's subjects included numerous ethnic groups (such as Germans, Italians, Romanians, Hungarians, etc.), the Slav proportion of the population (Poles, Ruthenians, Ukrainians, Czechs, Slovaks, Slovenes, Serbs, Bosniaks, and Croats) together formed a substantial—if not the largest—ethnic grouping.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.